Showing results (191-200 of 218) with videos related to

Sort By:
Pageof 22
American Journal of Ophthalmology|February 12, 2013
Primary and secondary congenital glaucoma: baseline features from a registry at King Khaled Eye Specialist Hospital, Riyadh, Saudi ArabiaFarhan F Alanazi, Jonathan C Song, Ahmed Mousa, et al.
Middle East African Journal of Ophthalmology|May 3, 2014
Development of a web-based glaucoma registry at King Khaled Eye Specialist Hospital, Saudi Arabia: a cost-effective methodologyBabar Zaman, Rajiv Khandekar, Sami Al Shahwan, et al.
Journal of Current Ophthalmology|August 19, 2021
Glaucoma Care of Incarcerated Patients at an Academic Institution: A Case-Control StudyLevi N Kanu, Daniel J Oh, Inae Jang, et al.
Investigative Ophthalmology & Visual Science|December 11, 2014
Identification of multiple DNA copy number alterations including frequent 8p11.22 amplification in conjunctival squamous cell carcinomaLaura Asnaghi, Hind Alkatan, Alka Mahale, et al.
JAMA Ophthalmology|February 21, 2020
Glaucoma Care of Prison Inmates at an Academic HospitalLevi N Kanu, Inae Jang, Daniel J Oh, et al.
European Journal of Ophthalmology|June 23, 2020
Eyelid sebaceous gland carcinoma: An assessment of the T classification of the American Joint Committee of Cancer TNM staging system 8th versus 7th editionFatimah AlHammad, Deepak P Edward, Hind M Alkatan, et al.
Frontiers in Medicine|April 2, 2026
Correction: Toward a clearer vision: epidemiology and symptom-based clinical patterns of dry eye disease in the Saudi populationMariam M AlEissa, Ahmed Mousa, Hala A Alosimi, et al.
Frontiers in Medicine|February 25, 2026
Toward a clearer vision: epidemiology and symptom-based clinical patterns of dry eye disease in the Saudi populationMariam M AlEissa, Ahmed Mousa, Hala A Alosimi, et al.
Middle East African Journal of Ophthalmology|December 21, 2016
Bottle Characteristics of Topical International Glaucoma Medications versus Local Brands in Saudi ArabiaNasser Al-Jumaian, Rizwan Malik, Rajiv Khandekar, et al.
European Journal of Ophthalmology|March 3, 2021
Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucomaAmy A Mehta, Levi N Kanu, Shalini Sood-Mendiratta, et al.
Pageof 22